DelphX Announces Non-Brokered Unit Private Placement and Update on OTC Quotation
The secondary US quotation may end in the coming months, while the primary TSX Venture Exchange listing remains unaffected.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
DelphX Capital Markets (DPXCF) has commenced a non-brokered private placement targeting gross proceeds of up to approximately C$70,000. The offering comprises up to 7,000,000 units at C$0.01 each, with each unit containing one common share and one warrant exercisable at C$0.06 for two years from issuance. DelphX expects closing on or before October 26, 2026, subject to TSX Venture Exchange approval.
The DPXCF quotation has moved to Pink Limited. DelphX does not intend to maintain its OTC quotation, which may end in the coming months. Its primary TSX Venture Exchange listing under DELX and holders' shareholdings are unchanged.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate point. Forward-looking: it has not happened yet and may not happen.The private placement targets up to approximately C$70,000 in gross proceeds.
- Minor point. Forward-looking: it has not happened yet and may not happen.DelphX expects the offering to close on or before October 26, 2026.
Negative
- Moderate point. Forward-looking: it has not happened yet and may not happen.Up to 7,000,000 units at C$0.01 each include one share and one warrant, creating dilution.
- Minor point. Forward-looking: it has not happened yet and may not happen.Each warrant permits another share purchase at C$0.06 for two years from issuance, creating potential further dilution.
- Minor point. Forward-looking: it has not happened yet and may not happen.The DPXCF quote moved to Pink Limited; DelphX will not maintain it, and it may end in coming months.
- Minor point. Forward-looking: it has not happened yet and may not happen.Offering completion remains subject to TSX Venture Exchange approval.
- Minor point. Forward-looking: it has not happened yet and may not happen.Issued securities face a four-month-plus-one-day hold and an Exchange Hold Period because units cost less than C$0.05.
- Minor point. Forward-looking: it has not happened yet and may not happen.DelphX may pay finder's fees to eligible finders under TSX Venture Exchange policies.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Toronto, Ontario and New York, New York--(Newsfile Corp. - October 19, 2026) - DelphX Capital Markets Inc. (TSXV: DELX) (OTC Pink: DPXCF) ("DelphX" or the "Company"), a leader in the development of new classes of structured products, announces that it has commenced a non-brokered private placement of up to 7,000,000 units of the Company (the "Units") at a subscription price of C
Each Unit consists of one common share of the Company (a "Common Share") and one Common Share purchase warrant (a "Warrant"). Each Warrant entitles the holder to purchase one additional Common Share at an exercise price of C
The Company expects to close the Offering on or before October 26, 2026.
In connection with the Offering, DelphX may elect to pay finder's fees to eligible finders in accordance with the policies of the TSX Venture Exchange. Details of any finder's fees paid will be announced at a later date.
DelphX intends to use the net proceeds of the Offering for working capital and corporate overhead. No more than
Completion of the Offering is subject to the approval of the TSX Venture Exchange. The securities issued pursuant to the Offering will be subject to a hold period of four months plus one day from the date of issuance and, as the Units are priced at less than C
OTC Markets Quotation
DelphX's common shares are quoted in the United States on OTC Markets under the symbol "DPXCF," and that quotation has moved to the Pink Limited market. The Company does not intend to maintain its OTC quotation, and the DPXCF quote may end in the coming months. The OTC quotation is a secondary US quote only. The Company's primary listing on the TSX Venture Exchange under the symbol "DELX" is unaffected.
Holders of DPXCF shares own the same common shares that trade on the TSX Venture Exchange. Their shareholdings do not change. Shareholders who hold their shares through a US brokerage account should contact their broker about transferring their position to an account that can trade on the TSX Venture Exchange. Registered shareholders can contact the Company's transfer agent, Odyssey Trust Company, at 1-888-290-1175 (toll-free, Canada and US), 1-587-885-0960 (direct), or shareholders@odysseytrust.com.
About DelphX Capital Markets Inc.
DelphX is a technology and financial services company focused on developing and distributing the next generation of structured products. Through its special purpose vehicle Quantem LLC, the Company enables broker dealers to offer new private placement securities that provide for both fixed income and cryptocurrency solutions. The new DelphX securities will enable dealers and their qualified institutional investors (QIBs) accounts to competitively structure, sell and make markets in:
Collateralized put options (CPOs) that provide secured rating downgrade protection for underlying corporate bonds and/or protection from losses in cryptocurrency holdings;
Collateralized reference notes (CRNs) that enable investors to take on a capped rating downgrade and/or cryptocurrency loss exposure of an underlying security or cryptocurrency in exchange for attractive returns.
All CPOs and CRNs are fully collateralized and held in custody by US Bank. CPOs and CRNs are proprietary products created and owned by DelphX Capital Markets.
For more information about DelphX, please visit www.delphx.com.
For further information, please contact:
George Wentworth, General Manager
DelphX Capital Markets Inc.
george.wentworth@delphx.com
(718) 509-2160
Forward-Looking Statements
This news release contains "forward-looking information" within the meaning of applicable Canadian securities laws, including statements regarding the proposed non-brokered private placement, the anticipated gross proceeds, the expected closing date, the intended use of proceeds, the Company's intention not to maintain its OTC quotation and the timing of any end to the DPXCF quotation. Forward-looking information is based on the Company's current expectations and assumptions and is subject to risks and uncertainties that could cause actual results to differ materially, including the risk that the Offering is not completed on the terms contemplated, by the expected date or at all, that the Offering is not fully subscribed, that regulatory approval from the TSX Venture Exchange is not obtained, and that the timing or manner in which the DPXCF quotation ends differs from what the Company expects. Readers are cautioned not to place undue reliance on forward-looking information, which speaks only as of the date of this release. The Company undertakes no obligation to update such information except as required by law.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/319297
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What are the terms of DelphX's private placement?
DelphX is offering up to 7,000,000 units at C$0.01 each for gross proceeds of up to approximately C$70,000. Each unit includes one common share and one warrant to buy an additional common share at C$0.06 for two years from issuance.
How does DelphX plan to use the private placement proceeds?
DelphX intends to use the net proceeds for working capital and corporate overhead. No more than 10% of gross proceeds will fund investor relations activities.